Evidence map›Paper›PMID 40977243›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Development and Clinical Evaluation of a Multiplexed Health Surveillance Panel Using Ultra High-Throughput PRM-MS in an Inflammatory Bowel Disease Cohort.

Qin Fu, Philip M Remes, Jihyeon Lee, Cristina Jacob, Dalin Li, Manasa Vegesna, Koen Raedschelders, Ali Haghani, Emebet Mengesha, Philip Debbas and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Qin Fu *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Philip M Remes *Thermo Fisher Scientific, San Jose, CA, USA.
Jihyeon LeeCedars-Sinai Medical Center, Los Angeles, CA, USA.
Cristina JacobThermo Fisher Scientific, San Jose, CA, USA.
Dalin LiCedars-Sinai Medical Center, Los Angeles, CA, USA.
Manasa VegesnaCedars-Sinai Medical Center, Los Angeles, CA, USA.
Koen RaedscheldersCedars-Sinai Medical Center, Los Angeles, CA, USA.
Ali HaghaniCedars-Sinai Medical Center, Los Angeles, CA, USA.
Emebet MengeshaCedars-Sinai Medical Center, Los Angeles, CA, USA.
Philip DebbasCedars-Sinai Medical Center, Los Angeles, CA, USA.
Esthelle HoedtCedars-Sinai Medical Center, Los Angeles, CA, USA.
Sandy JoungCedars-Sinai Medical Center, Los Angeles, CA, USA.
Susan ChengCedars-Sinai Medical Center, Los Angeles, CA, USA.
Scott PetermanThermo Fisher Scientific, San Jose, CA, USA.
Justyna Fert-BoberCedars-Sinai Medical Center, Los Angeles, CA, USA.
Gil Y MelmedCedars-Sinai Medical Center, Los Angeles, CA, USA.
Dermot P B McGovernCedars-Sinai Medical Center, Los Angeles, CA, USA.
Christopher I MurrayCedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-5055-4875
Jennifer E Van EykCedars-Sinai Medical Center, Los Angeles, CA, USA.

Funding

Mapping genes for IBD by admixture LD in Puerto RicansU01DK062413 · CEDARS-SINAI MEDICAL CENTER · 2002 to 2025
$1.9M
National Institute of Diabetes and Digestive and Kidney Disease U01DK062413National Institute of Diabetes and Digestive and Kidney Disease U01DK124019National Institutes of Health National Heart, Lung, and Blood Institute HL155346-01A1NHLBI NIH HHS R01 HL155346NIDDK NIH HHS U01 DK062413NIDDK NIH HHS U01 DK124019
6 · The paper itself

Abstract

Despite advances in clinical proteomics, translating protein biomarker discoveries into clinical use remains challenging due to the technical complexity of the validation process. Targeted MS-based proteomic approaches such as parallel reaction monitoring (PRM) offer sensitive and specific assays for biomarker translation. In this study, we developed a multiplex PRM assay using the Stellar mass spectrometry platform to quantify 57 plasma proteins, including 24 FDA-approved biomarkers. Loading curves (11 points) were performed at 4 sample throughputs (100, 144, 180, and 300 samples per day) using independently optimized and scheduled PRM methods. Following optimization, an inflammatory bowel disease (IBD) cohort of plasma samples (493 IBD, 509 matched controls) was analyzed at a throughput of 180 samples per day. To monitor system performance, the study also included over 1000 additional injections for system suitability tests, low-, middle-, and high-quality controls, washes, and blanks. Using this approach, we observed high quantifiability (linearity, sensitivity, and reproducibility) in the PRM assay and consistent data acquisition across a large cohort. We also validated the candidate IBD markers, C-reactive protein and orosomucoid protein, identified in a recent discovery experiment.

Indexed as

Blood ProteinsInflammatory Bowel DiseasesMass SpectrometryBiomarkersCohort StudiesHigh-Throughput Screening AssaysHumansProteomicsBiomarkersBlood ProteinsClinical biomarker translationInflammatory bowel diseaseTargeted peptidesValidation proteomics

Identifiers

PMID40977243
PMCPMC12603970

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.